Intranasal flu vaccine: Phase III Update

AVIR began the second year of vaccinations in its Phase III efficacy trial in 1,602 children. Patients who were in the trial last year will

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE